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Introduction
Dobutamine (DOB) is the actual recommended b-adrener-
gic inotropic drug to support sepsis-induced myocardial
dysfunction when cardiac output index is still low after
preload correction. In this context, DOB cardiovascular
response predicts outcome in septic shock. Alternative
supportive and safer therapies are however mandatory
because:
1) only 35-45% of septic patients do respond to DOB,
and
2) numerous side-effects of DOB can be observed,
including potential harmful impact on cardiomyocyte
function. Apelin (APLN) is a powerful inotrope, is
widely expressed by the cardiovascular system with its
receptor APJ-R, and should be considered as an alterna-
tive noncatecholaminergic support.
Objectives
Perform a comparative evaluation of APLN-13 (APLN
active peptide) vs DOB in terms of hemodynamic efficacy,
cardioprotection and outcome in a model of “sepsis-
induced cardiac dysfunction”.
Methods
A rat model of LPS-induced myocardial dysfunction
(E. Coli 055:B5, 10-12mg/kg intraperitoneal).
Interventions
APLN-13 vs DOB (0.23 vs 7.5µg/kg/min i.v continuous
infusion respectively, as determined by preliminary





In vivo: echocardiography, final hemodynamics; urine
output, weight and plasma volume variation, survival
study, ex vivo: Langendorff dP/dt, in vitro: APJ-R and
beta1-adrenergic receptor (AR) myocardial expressions,
Pi3K/Akt/GSK3/mTOR activation-expression profiles,
cTnI (troponin, myocardial injury) and cleaved caspase-
3 (apoptosis).
Results
Both drugs restored LPS-induced fall of left ventricular
ejection fraction (LVEF) with dominant chronotropic
impact and mean arterial pressure (MAP) restoration
for DOB, and lower peripheral vascular resistances
(PVR) for APLN. APJ-R but not beta1 AR myocardial
expressions were upregulated by LPS challenge (p<
0.05). The deepness the induced LVEF drop, the higher
the dP/dt response to APLN but not to DOB (p< 0.05).
In 18h LPS-challenged hearts, Langendorff assays peak
dP/dt responses were 3nM and 100nM for APLN and
DOB, respectively (p< 0.05). Combining fluid resuscita-
tion with APLN infusion declined urine output (UO)
with plasma volume (PV) expansion, whereas DOB
induced less PV expansion but more UO (p < 0.05).
Survival proportions were clearly distinctive (p < 0.05).
APLN further dampened down LPS-induced overpho-
sphorylation/inhibition of Pi3K/Akt/mTOR/GSK3 and
reduced injury/apoptosis (i.e. cTNI and cleaved caspase-
3 expressions).
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Conclusions
APLN potentially offers distinctive mechanisms of hemo-
dynamics, cardioprotective effects, and survival benefits,
over DOB. Chemical optimization of APLN-13 with more
extensive preclinical data, would pave the way for first
phase clinical trials.
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Figure 1 APLN survival
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